Apolipoprotein Inhibitor

Apolipoprotein Inhibitors (39):

Cat. No.	Product Name	Effect	Purity

HY-108764

Mipomersen sodium	Inhibitor
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH).

HY-145727A

Volanesorsen sodium	Inhibitor	98.51%
Volanesorsen (ISIS 304801) sodium is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen sodium is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes.

HY-108764B

Mipomersen sodium scrambled negative control	Inhibitor	98.20%
Mipomersen sodium scrambled negative control is the sequence scrambled negative control of Mipomersen sodium.

HY-122208

SGA360	Inhibitor	99.93%
SGA360 suppress inflammatory SAA1 signaling in an AHR-dependent manner through a mechanism that does not require AHR binding to its cognate response element (partial antagonist).

HY-145727

Volanesorsen	Inhibitor
Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes.

HY-W011824

2′-O-Methyluridine	Inhibitor	99.92%
2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.

HY-112798

PH-002	Inhibitor	98.48%
PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that could rescue impairments of mitochondrial motility and neurite outgrowth.

HY-132820

Inaxaplin	Inhibitor	99.44%
Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.

HY-147425A

Zerlasiran sodium	Inhibitor
Zerlasiran (SLN360) sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

HY-18778

Obicetrapib	Inhibitor	99.93%
Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

HY-148647

Mipomersen	Inhibitor
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH).

HY-164740A

Plozasiran sodium	Inhibitor
Plozasiran sodium is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.

HY-143200

OSBPL7-IN-1	Inhibitor	99.84%
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.

HY-153491

Olezarsen	Inhibitor
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease.

HY-153491A

Olezarsen sodium	Inhibitor
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) sodium is a GalNAc-modified antisense oligonucleotide. Olezarsen sodium binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen sodium reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen sodium is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease.

HY-164740

Plozasiran	Inhibitor	99.00%
Plozasiran is an siRNA targeting APOC3 for the study of mixed hyperlipidemia.

HY-141885

APOL1-IN-1	Inhibitor	99.85%
APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD).

HY-177653A

Opemalirsen sodium	Inhibitor
Opemalirsen sodium is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.

HY-147425

Zerlasiran	Inhibitor
Zerlasiran (SLN360) is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

HY-W011824R

2′-O-Methyluridine (Standard)	Inhibitor
2′-O-Methyluridine (Standard) is the analytical standard of 2′-O-Methyluridine (HY-W001824). This product is intended for research and analytical applications. 2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.